HCV infection and liver transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease and a primary indication for liver transplantation.
• Viral recurrence, specifically HCV reinfection, poses a significant challenge, limiting long-term graft and patient survival post-transplantation.

Purpose of the Study:

• To evaluate the incidence and impact of HCV reinfection on liver graft outcomes.
• To assess the efficacy of current treatment modalities for post-transplant HCV hepatitis.
• To determine the medium and long-term survival rates of patients undergoing liver transplantation for HCV cirrhosis.

Main Methods:

• Demonstration of HCV RNA sequence homology in pre- and post-transplant patient samples.
• Monitoring of HCV RNA levels, viral genotypes, and histological findings (acute hepatitis, chronic hepatitis, cirrhosis) in graft biopsies.
• Analysis of patient survival rates and graft outcomes at 5-year intervals.

Main Results:

• HCV reinfection is nearly constant post-transplantation, with 90% of patients showing detectable HCV RNA.
• Acute lobular hepatitis occurred in 75% of patients within a median of 4 months.
• Five-year actuarial rates for graft hepatitis, chronic hepatitis, and cirrhosis were 75%, 60%, and 8%, respectively.
• HCV RNA levels post-transplantation correlated with acute graft hepatitis; genotype 1b was associated with increased prevalence and severity.

Conclusions:

• Liver transplantation is a viable option for end-stage HCV cirrhosis, offering good medium-term survival (78% at 5 years).
• HCV reinfection is frequent and impacts graft health, necessitating the development of effective prevention and treatment strategies.
• Long-term graft and patient survival post-HCV liver transplantation require further investigation and improved therapeutic interventions.